GAMMAGARD LIQUID - SC Administration
Protecting life's moments with consistent trough levels1,2
In the SC administration of GAMMAGARD LIQUID clinical study1
- The median Ig trough level during intravenous treatment was 1010 mg/dL (95% CI: 940-1240)
- The mean Ig trough level during intravenous treatment was 1050 ± 260 mg/dL2
- The median Ig trough level during subcutaneous treatment was 1260 mg/dL (95% CI: 1060-1400)a
- The mean Ig trough level during subcutaneous treatment was 1202 ± 282 mg/dLa
aTaken from pharmacokinetic analysis at the end of study period 4.
- Multicenter, prospective, open-label, study (N=49 adults [n=31 16 years or older], adolescents [n=4 between 12 years and <16], and children [n=14 between 2 years and <12])
- 4 study periods + optional extension
- Mean weekly subcutaneous doses ranged from 182-191 mg/kg
Important Considerations for Dosing1
- Adjust dose according to IgG levels and clinical response as the frequency and dose of IgG treatment may vary from patient to patient
- The patient's clinical response should be the primary consideration in dose adjustment
References: 1. GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% [Prescribing Information]. Westlake Village, CA: Baxalta US Inc. 2. Wasserman RL, Melamed I, Kobrynski L, et al. Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease. J Clin Immunol. 2011;31(3):323-331.